444607-92-5

Usage

Tert-butyl ester derivative

The compound is derived from isoindoline-1,2-dicarboxylic acid by replacing one of the hydrogen atoms with a tert-butyl group, resulting in an ester functional group.

Usage in synthesis

1-tert-Butyl 2-Methyl isoindoline-1,2-dicarboxylate is used as a raw material in the synthesis of various organic compounds, such as pharmaceuticals, dyes, and polymers.

Potential applications in medicine

Due to its biological activity, this chemical has potential applications in the field of medicine, including its possible use as an anti-tumor agent.

Academic and industrial research

The compound is utilized in research settings for its unique chemical properties and potential uses in various fields, contributing to the advancement of scientific knowledge and practical applications.

Upstream product

• 74-88-4 methyl iodide 
• 221352-46-1 (R,S)-N-Boc-1,3-dihydro-2H-isoindole carboxylic acid 
• 221352-46-1 2-(tert-butoxycarbonyl)isoindoline-1-carboxylic acid 
• 18107-18-1 diazomethyl-trimethyl-silane 
• 1359987-44-2 O-tert-butyl 1-(tributylstannyl)isoindoline-2-carboxylate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 60651-97-0 Methyl 1,3-dihydro-2H-isoindole-1-carboxylate Hydrochloride 
• 480-91-1 oxisoindole 
• 111605-85-7 methyl (+/-)-1,3-dihydro-2H-isoindole-1-carboxylate 
• 1367468-00-5 tert-butyl (+/-)-1-cyano-1,3-dihydro-2H-isoindole-2-carboxylate 
• 96016-96-5 1,3-Dihydro-2H-isoindole-1-carboxylic Acid Hydrochloride 

Downstream Products

• 111605-85-7 methyl (+/-)-1,3-dihydro-2H-isoindole-1-carboxylate 
• 914298-94-5 2-(5-chloro-2,4-bis-methoxymethoxybenzoyl)-2,3-dihydro-1H-isoindole-1-carboxylic acid methyl ester 
• 914298-27-4 2-(5-chloro-2,4-bis-methoxymethoxybenzoyl)-2,3-dihydro-1H-isoindole-1-carboxylic acid 
• 1297473-21-2 C₂₀H₂₂N₂O₃ 
• 1297473-22-3 C₂₀H₂₁ClN₂O₃ 
• 1265584-96-0 C₂₀H₂₀Cl₂N₂O₃ 
• 791822-57-6 1-phenylmethyl-1,3-dihydro-2H-isoindole-1,2-dicarboxyIic acid, 2-tert-butyl ester, 1-methyl ester 

Relevant academic research and scientific papers

Stereospecific ring-expanding skeletal rearrangement of isoindoline to tetrahydroisoquinoline via a sequential aziridine ring formation/opening

A stereospecific skeletal rearrangement of isoindoline to tetrahydroisoquinoline was developed under Appel reaction conditions using a combination of PPh3 and CCl4. This reaction involves a sequential ring formation/opening of a labile aziridine and enables the construction of a quaternary carbon center, offering a highly useful method for accessing 3,3,4-trisubstituted tetrahydroisoquinolines.

BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AGONISTS.

This invention relates to compounds that are agonists of the muscarinic M1 receptor and/or M4 receptor and which are useful in the treatment of muscarinic M1/M4 receptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds include those according to formula 1, or a salt thereof, wherein Q, R1 , R2, R3 and R4 are as defined herein.

Synthesis of arylglycine and mandelic acid derivatives through carboxylations of α-amido and α-acetoxy stannanes with carbon dioxide

Incorporation reactions of carbon dioxide (CO2) with N-Boc-α-amido and α-acetoxy stannanes were developed using CsF as a mild tin activator. Monoprotected α-amido stannanes could be used, and the corresponding arylglycine derivatives were obtained in moderate-to-high yields under 1 MPa (10 atm) of CO2 pressure. α-Acetoxy stannanes also underwent carboxylation to afford mandelic acid derivatives in excellent yields under ambient CO2 pressure. Both transformations enabled the synthesis of α-tertiary and α-quaternary carboxylic acid derivatives. In addition, the chirality of (S)-N-tert-butylsulfonyl-α- amido stannanes was transferred with up to 90% inversion of configuration at 100 °C.

Discovery of isoindoline and tetrahydroisoquinoline derivatives as potent, selective PPARδ agonists

Small molecule isoindoline and tetrahydroisoquinoline derivatives have been identified as selective agonists of human peroxisome proliferator-activated receptor δ (PPARδ. Compound 18 demonstrated efficacy in a biomarker for increased fatty acid oxidation,

AMIDE RESORCINOL COMPOUNDS

The present invention is directed to amide resorcinol compounds and pharmaceutically acceptable salts and solvates thereof, their synthesis, and their use as HSP-90 inhibitors.

AMIDE RESORCINOL COMPOUNDS

The present invention is directed to compounds of formula (I), and pharmaceutically acceptable salts and solvates thereof, their synthesis, and their use as HSP-90 inhibitors.

Piperidinyl-alpha-aminoamide modulators of chemokine receptor activity

The present invention is directed to compounds of the formula I: (wherein R1, R2, R3, R4, R5, R6, W, X, Z, m and n are defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptor CCR-2.

ACYL ISOINDOLINE DERIVATIVES AND ACYL ISOQUINOLINE DERIVATIVES AS ANTI-VIRAL AGENTS

Anti-viral agents of Formula (I) wherein: R3 represents aryl or heteroaryl; R4 represents one or two substituents independently selected from hydrogen, C 1-6alkyl, halo, ORA , C(O)NRBR

N-arylsulfonyl aza-bicyclic derivatives as potent cell adhesion inhibitors

Compounds of Formula I are antagonists of VLA-4 and/or alpha4/beta7, and as such are useful in the inhibition or prevention of cell adhesion and cell-adhesion mediated pathologies. These compounds may be formulated into pharmaceutical compositions and are suitable for use in the treatment of AIDS-related dementia, allergic conjunctivitis, allergic rhinitis, Alzheimer's disease, asthma, atherosclerosis, autologous bone marrow transplantation, certain types of toxic and immune-based nephritis, contact dermal hypersensitivity, inflammatory bowel disease including ulcerative colitis and Crohn's disease, inflammatory lung diseases, inflammatory sequelae of viral infections, meningitis, multiple sclerosis, multiple myeloma, myocarditis, organ transplantation, psoriasis, pulmonary fibrosis, restenosis, retinitis, rheumatoid arthritis, septic arthritis, stroke, tumor metastasis, uveititis, and type I diabetes.

N-arylsulfonyl aryl aza-bicyclic derivatives as potent cell adhesion inhibitors

Compounds of Formula I are antagonists of VLA-4 and/or alpha4/beta7, and as such are useful in the inhibition or prevention of cell adhesion and cell-adhesion mediated pathologies. These compounds may be formulated into pharmaceutical compositions and are suitable for use in the treatment of AIDS-related dementia, allergic conjunctivitis, allergic rhinitis, Alzheimer's disease, asthma, atherosclerosis, autologous bone marrow transplantation, certain types of toxic and immune-based nephritis, contact dermal hypersensitivity, inflammatory bowel disease including ulcerative colitis and Crohn's disease, inflammatory lung diseases, inflammatory sequelae of viral infections, meningitis, multiple sclerosis, multiple myeloma, myocarditis, organ transplantation, psoriasis, pulmonary fibrosis, restenosis, retinitis, rheumatoid arthritis, septic arthritis, stroke, tumor metastasis, uveititis, and type I diabetes.